<tt id="6hsgl"><pre id="6hsgl"><pre id="6hsgl"></pre></pre></tt>
          <nav id="6hsgl"><th id="6hsgl"></th></nav>
          国产免费网站看v片元遮挡,一亚洲一区二区中文字幕,波多野结衣一区二区免费视频,天天色综网,久久综合给合久久狠狠狠,男人的天堂av一二三区,午夜福利看片在线观看,亚洲中文字幕在线无码一区二区

          Companies

          Bayer HealthCare relocates

          By Liu Jie (China Daily)
          Updated: 2011-03-25 09:44
          Large Medium Small

          Bayer HealthCare relocates

          An advertisement for White and Black, a cold medicine, in a subway station in Beijing. Bayer HealthCare bought the brand in 2006 for 100 million euros ($141 million). [Photo / China Daily] 

          The drugmaker says relocation is scheduled to be completed by June this year

          BEIJING - The pharmaceutical company Bayer HealthCare (BHC) is moving its general medicine headquarters to Beijing, which is a first among multinational drugmakers.

          "We expect this step to speed up the decision-making process and to promote more general efficiency in our day-to-day work," Chris H. Lee, the managing director of BHC China, said on Thursday. "For Chinese patients, the relocation of our general medicine headquarters will allow for more efficient product launches in China and focus greater attention on unmet local medical needs."

          BHC, a subsidiary of Germany's Bayer AG, said the decision to move was made late last year and the relocation is expected to be completed in June of this year.

          Bayer HealthCare relocates

          Chris H. Lee, managing director of BHC China?

          BHC plans to introduce some 20 new products in China over the next five years, including those in the fields of oncology, cardiology, women's healthcare, and diagnostic imaging. Two new products also will be launched this year. The company unveiled four new products and undertook 22 clinical trials in China in 2010.

          Lee said that the increasing importance of the Chinese market and BHC's rapid growth in the country had led to the relocation. The company is one of the top three multinational drugmakers in China, with sales from the business growing above the industry average at 22 percent year-on-year in 2010, according to the independent medical care researcher IMS Health.

          General drugs account for 82 percent of the company's business. In this sector, Chinese sales contribute 12 percent to the global total. "What we do in China will have an effect on other developing economies," Lee said.

          According to IMS Health, China is now the world's third-largest pharmaceutical market, and is predicted to grow between 25 percent and 27 percent to more than $50 billion in 2011.

          In addition to moving its general medicine headquarters, BHC is moving to a regionalized structure by dividing the huge Chinese market into three regions; the central China unit will be based in Beijing, southern China will be controlled from Shanghai, and the operations center for the west of the country will be located in Chengdu.

          "The strategy will enable us to be customer-centric, to disaggregate operational complexity, be more flexible, and speed up operational decision-making at the frontline. It will help us to stay close to front-line employees and be more attentive to their needs and development," said Lee.

          Currently, the central region accounts for 45 percent of the company's business in China. The southern operations make up 35 percent, and the western region 20 percent. "We believe the western region will grow faster than the others," said the managing director.

          Related readings:
          Bayer HealthCare relocates China to be 3rd largest pharma market in 2011
          Bayer HealthCare relocates China lures global drug makers
          Bayer HealthCare relocates Chinese pharma sales to boost global demand
          Bayer HealthCare relocates Lilly to continue China expansion

          The company will also strengthen its sales force by adding 1,000 positions in 2011 in its core markets and lower-tier cities.

          Despite the current enthusiasm of multinational companies for merging or acquiring local counterparts, Lee said that "at the moment" the company is "focusing on organic expansion".

          But when there are good opportunities, the company will engage in mergers and acquisitions, he added.

          "It is a sort of shortcut for the multinationals to expand their product portfolios, obtain medicines tailored for local requirements and penetrate the grassroots market," said Guo Fanli, an analyst at the China Investment Consulting.

          In the "On-The-Counter" market, BHC paid 100 million euros ($141 million) for the cough and cold medicines portfolio of the domestic drugmaker Topsun Science and Technology Co Ltd in 2006.

           

          分享按鈕
          主站蜘蛛池模板: 国产一区二区丰满熟女人妻| 国产精品成人自产拍在线| 日本边吃奶边摸边做在线视频| chinese乱国产伦video| caoporn成人免费公开| 中文字幕有码无码AV| 91国内精品久久久久影院| 亚洲色成人一区二区三区| 一级欧美牲交大片免费观看| 日韩中文日韩中文字幕亚| 99久久久无码国产精品免费 | 精品少妇一区二区三区视频| 国产午夜福利视频在线| 国产又爽又黄又不遮挡视频| 无码国内精品久久人妻蜜桃| av中文字幕在线资源网| 日韩大片看一区二区三区| 护士大爆乳双腿张开自慰喷水| 91色老久久精品偷偷蜜臀| AV最新高清无码专区| 亚洲 中文 欧美 日韩 在线| 日韩大片一区二区三区| 精品无码人妻一区二区三区| 久久精品国产亚洲夜色AV网站| 四虎国产精品永久在线下载| 日韩中文字幕国产精品| 狠狠亚洲超碰狼人久久| 白丝乳交内射一二三区| 国内精品卡一卡二卡三| 国产精品中文一区二区| 国产精品va在线观看无码不卡| 国内熟妇人妻色在线视频| 国产综合久久久久久鬼色| 性欧美三级在线观看| 久久久久久久波多野结衣高潮| 久久精品国产视频在热| 狠狠爱五月丁香亚洲综| 亚洲bt欧美bt精品| 国产成人精彩在线视频| 亚洲成av人在线播放无码| 国产精品中文字幕一区|